L. Ek

797 total citations
21 papers, 520 citations indexed

About

L. Ek is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Oncology. According to data from OpenAlex, L. Ek has authored 21 papers receiving a total of 520 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Surgery, 5 papers in Cardiology and Cardiovascular Medicine and 5 papers in Oncology. Recurrent topics in L. Ek's work include Venous Thromboembolism Diagnosis and Management (4 papers), Pharmacological Effects and Assays (4 papers) and Lung Cancer Research Studies (3 papers). L. Ek is often cited by papers focused on Venous Thromboembolism Diagnosis and Management (4 papers), Pharmacological Effects and Assays (4 papers) and Lung Cancer Research Studies (3 papers). L. Ek collaborates with scholars based in Sweden, Denmark and United Kingdom. L. Ek's co-authors include Bengt Åblad, Jan‐Arne Björkman, Tommy Abrahamsson, Janet M. Allen, P. Gjörstrup, S.R. Bloom, Enar Carlsson, Bengt Bergman, Pär‐Ola Bendahl and Mattias Belting and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

L. Ek

21 papers receiving 464 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
L. Ek Sweden 11 151 137 98 98 80 21 520
J. Bohner Germany 13 187 1.2× 90 0.7× 112 1.1× 27 0.3× 39 0.5× 35 594
Joris van Rossum Netherlands 13 69 0.5× 104 0.8× 190 1.9× 80 0.8× 142 1.8× 20 497
Linda A. Leis United States 10 133 0.9× 110 0.8× 31 0.3× 31 0.3× 44 0.6× 18 427
Andrew J. Johnson United Kingdom 12 210 1.4× 73 0.5× 52 0.5× 21 0.2× 41 0.5× 24 464
Elke Schüler Germany 11 175 1.2× 115 0.8× 75 0.8× 22 0.2× 36 0.5× 13 473
Masashi Ukai Japan 14 57 0.4× 129 0.9× 75 0.8× 55 0.6× 6 0.1× 30 792
B Astruc France 9 101 0.7× 84 0.6× 74 0.8× 47 0.5× 7 0.1× 21 689
Stanley R. Jolly United States 13 349 2.3× 137 1.0× 167 1.7× 23 0.2× 9 0.1× 31 716
Andrea Grandi Italy 13 174 1.2× 47 0.3× 32 0.3× 25 0.3× 11 0.1× 35 376
A. J. Drake‐Holland United Kingdom 14 380 2.5× 97 0.7× 92 0.9× 41 0.4× 20 0.3× 38 604

Countries citing papers authored by L. Ek

Since Specialization
Citations

This map shows the geographic impact of L. Ek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Ek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Ek more than expected).

Fields of papers citing papers by L. Ek

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Ek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Ek. The network helps show where L. Ek may publish in the future.

Co-authorship network of co-authors of L. Ek

This figure shows the co-authorship network connecting the top 25 collaborators of L. Ek. A scholar is included among the top collaborators of L. Ek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Ek. L. Ek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bendahl, Pär‐Ola, L. Ek, Bengt Bergman, et al.. (2019). Low-molecular-weight heparin adherence and effects on survival within a randomised phase III lung cancer trial (RASTEN). European Journal of Cancer. 118. 82–90. 6 indexed citations
2.
Bendahl, Pär‐Ola, Yohei Hisada, Søren Risom Kristensen, et al.. (2018). Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer: A sub-study of RASTEN - A randomized trial with low molecular weight heparin. PLoS ONE. 13(11). e0207387–e0207387. 43 indexed citations
3.
Kirk, Alan, Malgorzata Kornaszewska, Kris Carron, et al.. (2017). A Multicenter, Prospective, Randomized, Controlled Trial Of Endobronchial Valve Treatment Vs Standard Of Care In Heterogeneous Emphysema (transform). American Journal of Respiratory and Critical Care Medicine. 195. 6 indexed citations
4.
Ek, L., Bengt Bergman, Pär‐Ola Bendahl, et al.. (2017). Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial. Annals of Oncology. 29(2). 398–404. 57 indexed citations
5.
Ek, L., Bengt Bergman, Pär‐Ola Bendahl, et al.. (2017). P1.15-007 Randomized Phase III Trial of Enoxaparin in Addition to Standard Treatment in Small Cell Lung Cancer: The RASTEN Trial. Journal of Thoracic Oncology. 12(11). S2045–S2046. 2 indexed citations
6.
Carlsson, Björn, et al.. (2015). Cardiac Effects of �-Adrenergic Receptor Antagonists. Advances in cardiology. 12(0). 290–302. 2 indexed citations
7.
Hermes, Andreas, Bengt Bergman, Roy M. Bremnes, et al.. (2007). A randomized phase III trial of irinotecan plus carboplatin versus etoposide plus carboplatin in patients with small cell lung cancer, extensive disease (SCLC-ED): IRIS-Study. Journal of Clinical Oncology. 25(18_suppl). 7523–7523. 8 indexed citations
8.
Christiansen, J. A., L. Ek, & E Tegner. (1997). Pinch grafting of leg ulcers. A retrospective study of 412 treated ulcers in 146 patients.. Acta Dermato Venereologica. 77(6). 471–473. 23 indexed citations
9.
Ek, L. & E Hedfors. (1993). Behçet's disease: a review and a report of 12 cases from Sweden.. Acta Dermato Venereologica. 73(4). 251–254. 18 indexed citations
10.
Wight, Richard, et al.. (1992). A double blind comparison of intranasal budesonide 400 ?g and 800 ?g in perennial rhinitis. Clinical Otolaryngology. 17(4). 354–358. 32 indexed citations
11.
Allen, Janet M., P. Gjörstrup, Jan‐Arne Björkman, et al.. (1986). Studies on cardiac distribution and function of neuropeptide Y. Acta Physiologica Scandinavica. 126(3). 405–411. 77 indexed citations
12.
Abrahamsson, Tommy, G. Adler, Jan‐Arne Björkman, et al.. (1985). The distribution of atenolol and metoprolol into ischemic and non-ischemic myocardium. Journal of Molecular and Cellular Cardiology. 17. 52–52. 2 indexed citations
13.
Abrahamsson, Tommy, et al.. (1985). Effects of metoprolol on ischemic myocardial regional function and oxygen supply/demand ratio in the dog. Journal of Molecular and Cellular Cardiology. 17. 53–53. 6 indexed citations
14.
Erfurth, Eva Marie, Nils E. Nordén, Pavo Hedner, Å. Nilsson, & L. Ek. (1984). Normal reference interval for thyrotropin response to thyroliberin: dependence on age, sex, free thyroxin index, and basal concentrations of thyrotropin.. Clinical Chemistry. 30(2). 196–199. 34 indexed citations
15.
Ek, L., Jan‐Arne Björkman, Enar Carlsson, & Birgitta Johansson. (1982). The haemodynamic effects of intravenous prenalterol and ouabain in conscious dogs. Acta Medica Scandinavica. 211(S659). 39–52. 3 indexed citations
16.
Åblad, Bengt, Enar Carlsson, L. Ek, & G. Johnsson. (1977). Mode of Action of Beta Blockers in Angina Pectoris. Scottish Medical Journal. 22(1). 52–63. 3 indexed citations
17.
Åblad, Bengt, Enar Carlsson, C Dahlöf, & L. Ek. (1976). Some Aspects of the Pharmacology of β-Adrenoreceptor Blockers. Drugs. 11(Supplement 1). 100–111. 21 indexed citations
18.
Åblad, Bengt, et al.. (1970). β-Adrenergic receptor blocking properties of three allyl-substituted phenoxypropanolamines. European Journal of Pharmacology. 13(1). 59–64. 16 indexed citations
19.
Åblad, Bengt, et al.. (1967). Pharmacological Properties of H 56/28—a ß‐Adrenergic Receptor Antagonist. Acta Pharmacologica et Toxicologica. 25(S2). 9–40. 144 indexed citations
20.
Björntorp, Per, L. Ek, S. Bertil Olsson, & G. Schröder. (1967). The Effect of a ß‐Adrenergic Receptor Antagonist (H 56/28) on Lipid Mobilization. Acta Pharmacologica et Toxicologica. 25(S2). 51–62. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J. Bohner Breakdown of academic impact, for papers by Joris van Rossum Breakdown of academic impact, for papers by Linda A. Leis Breakdown of academic impact, for papers by Andrew J. Johnson Breakdown of academic impact, for papers by Elke Schüler Breakdown of academic impact, for papers by Masashi Ukai Breakdown of academic impact, for papers by B Astruc Breakdown of academic impact, for papers by Stanley R. Jolly Breakdown of academic impact, for papers by Andrea Grandi Breakdown of academic impact, for papers by A. J. Drake‐Holland
Rankless by CCL
2026